Lung Cancer

Nicolas Girard, MD, discusses the next steps with durvalumab in non–small cell lung cancer.

Melissa L. Johnson, MD, discusses the potential utility of TROP2 as a therapeutic target for all-comers with solid tumor malignancies.

Routine computed tomography-based imaging scans identified abnormal ground-glass opacities and infiltrates indicative of COVID-19 in patients with lung cancer undergoing radiation therapy, enabling earlier diagnosis, treatment, and risk reducing measures.

MUSC Hollings Cancer Center researcher and radiation oncologist Graham Warren, MD, PhD, published a new study in the Journal of Thoracic Oncology detailing new findings and early markers of COVID-19 in lung cancer patients.

Janakiraman Subramanian, MD, discusses the standard of care in stage III non–small cell lung cancer.

Heather Wakelee, MD, shares insight on factors to consider when approaching the optimal first-line therapy for patients with EGFR-mutant advanced NSCLC.

Ani Balmanoukian, MD, Sandip P. Patel, MD, and Heather Wakelee, MD, review currently available treatment options for EGFR-mutant advanced NSCLC and discuss their approach to frontline therapy.

Liza C. Villaruz, MD, discusses updated data from the phase 3 CheckMate-227 trial examining nivolumab with or without ipilimumab in patients with non–small cell lung cancer. 

Edgardo S. Santos, MD, FACP, discusses the importance of identifying mechanisms of resistance in lung cancer.

Melissa Johnson, MD, discusses highlights from the 2021 ESMO Congress.

Erminia Massarelli, MD, MS, PhD, shares insight on potential barriers to appropriate molecular testing in patients with non–small cell lung cancer.

Experts take a broad look at how molecular profiling has impacted the treatment landscape of non–small cell lung cancer.

George Simon, MD, FACP, FCCP, discusses the importance of next-generation sequencing in patients with non–small cell lung cancer.

Luis E. Raez, MD, discusses the clinical implications of the phase 3 KEYNOTE-024 trial in non–small cell lung cancer.

Danny Nguyen, MD, discusses management strategies for mobocertinib-related gastrointestinal toxicities in EGFR exon 20 insertion–positive non–small cell lung cancer.

Maria Carmela Piccirillo, MD, discusses the safety profile of bevacizumab plus erlotinib in EGFR-mutated advanced nonsquamous non–small cell lung cancer.

Isabel Preeshagul, DO, MBS; Catherine Ann Shu, MD; and Ashish Saxena, MD, PhD, discuss the latest findings in small cell lung cancer based on studies that were presented during the 2021 ESMO Congress, 2021 World Conference on Lung Cancer, and 2021 ASCO Annual Meeting.

Isabel Preeshagul, DO, MBS; Catherine Ann Shu, MD; and Ashish Saxena, MD, PhD, share insight on the data with novel targeted agents with impressive efficacy in patients with lung cancer, as seen at the 2021 ESMO Congress and the 2021 World Conference on Lung Cancer.

Isabel Preeshagul, DO, MBS; Catherine Ann Shu, MD; and Ashish Saxena, MD, PhD, highlight results with immunotherapy in the neoadjuvant and stage IV setting in lung cancer that were presented at the 2021 World Conference on Lung Cancer and the 2021 ESMO Congress.

Isabel Preeshagul, DO, MBS; Catherine Ann Shu, MD; and Ashish Saxena, MD, PhD, discuss breakthroughs in adjuvant immunotherapy in lung cancer from data presented at the 2021 ESMO Congress and 2021 World Conference on Lung Cancer.

Miranda Gogishvili, MD, discusses the rationale for the phase 3 EMPOWER-Lung 3 trial in advanced or metastatic non–small cell lung cancer.

Antoinette Wozniak, MD, FACP, FASCO, highlights the importance of monitoring patients with lung cancer for toxicities and significant advances on the horizon that are expected to further expand the lung cancer armamentarium.

Dr. Johnson discusses the mechanism of action of VS-6766 alone and in combination with defactinib, expectations for the ongoing phase 2 RAMP 202 trial in KRAS-mutant non–small cell lung cancer, and where the combination could be used in practice pending further positive study results.

Canakinumab plus pembrolizumab and platinum-based doublet chemotherapy did not significantly improve progression-free survival or overall survival in previously untreated patients with locally advanced or metastatic non–small cell lung cancer, missing the primary end points of the phase 3 CANOPY-1 trial.

Ben Levy, Mark Socinski, and Stephen Liu describe the current treatment options for patients with ROS1+ NSCLC. They also summarize recent clinical data for agents that target ROS1.